Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

Treatment of uncontrolled asthma with dupilumab, an anti–interleukin-4 and anti–interleukin-13 receptor monoclonal antibody, in addition to usual therapy, led to a rate of severe exacerbations that was approximately 50% lower than the rate with placebo.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2018-06, Vol.378 (26), p.2486-2496
Hauptverfasser:	Castro, Mario, Corren, Jonathan, Pavord, Ian D, Maspero, Jorge, Wenzel, Sally, Rabe, Klaus F, Busse, William W, Ford, Linda, Sher, Lawrence, FitzGerald, J. Mark, Katelaris, Constance, Tohda, Yuji, Zhang, Bingzhi, Staudinger, Heribert, Pirozzi, Gianluca, Amin, Nikhil, Ruddy, Marcella, Akinlade, Bolanle, Khan, Asif, Chao, Jingdong, Martincova, Renata, Graham, Neil M.H, Hamilton, Jennifer D, Swanson, Brian N, Stahl, Neil, Yancopoulos, George D, Teper, Ariel
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Age Anti-Asthmatic Agents - adverse effects Anti-Asthmatic Agents - pharmacology Anti-Asthmatic Agents - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Asthma Asthma - classification Asthma - drug therapy Biomarkers Blood Bronchodilator Agents - therapeutic use Bronchodilators Child Clinical medicine Committees Cytokines Double-Blind Method Drug dosages Drug Therapy, Combination Eosinophilia Eosinophilia - chemically induced Female Forced Expiratory Volume - drug effects Humans Immunotherapy Inflammation Injections, Subcutaneous - adverse effects Intention to Treat Analysis Interleukin 13 Interleukin 4 Intervention Leukocytes (eosinophilic) Male Medicine Middle Aged Monoclonal antibodies Patient safety Pharmaceuticals Population Questionnaires Receptors, Interleukin-4 - antagonists & inhibitors Respiratory function Safety Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Treatment of uncontrolled asthma with dupilumab, an anti–interleukin-4 and anti–interleukin-13 receptor monoclonal antibody, in addition to usual therapy, led to a rate of severe exacerbations that was approximately 50% lower than the rate with placebo.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1804092